In the experimental autoimmune encephalomyelitis (EAE) model, oral riboflavin (20 mg/kg/day) ameliorated motor deficits, suppressed reactive oxygen species, and modulated immune signaling by downregulating interleukin-6 (IL-6) and enhancing brain-derived neurotrophic factor (BDNF) expression, reflecting combined antioxidant and anti-inflammatory effects (39, 40). Here, BDNF is linked to experimental autoimmune encephalomyelitis.